Chinese Firms Gain Millions from US Tariff Refunds, Boosting 2025 Profits
US tariff refunds are significantly benefiting Chinese enterprises, with over $38 million in rebates and accrued interest distributed to five listed companies since last month, enhancing their financial performance.
These firms, mainly active in automotive and healthcare, received an average refund of $7.64 million—ranging from 13.12% to 53.58% of their 2025 net profits—through accounts of their US subsidiaries.
Huahai Pharmaceutical’s US branch secured $14.2 million in refunds, equating to 36.36% of its 2025 net profit, which the company stated would affect second-half earnings as reported in its exchange filing.
The refunds are expected to increase importers’ purchasing power and willingness to restock
Additional disclosures indicate that over a dozen Chinese companies have filed reports or communicated with investors about tariff refund applications.
Zhou Zheng, an analyst at Aijian Securities, noted that the rebates extend benefits to OEMs by strengthening importers’ financial capacity and reducing price negotiation pressures, ultimately aiding Chinese manufacturers.
